Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Liabilities and Shareholders Equity (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $777.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 27.82% year-over-year to $777.8 million, compared with a TTM value of $2.4 billion through Dec 2025, up 22.41%, and an annual FY2025 reading of $777.8 million, up 27.82% over the prior year.
  • Liabilities and Shareholders Equity was $777.8 million for Q4 2025 at Spyre Therapeutics, up from $504.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $777.8 million in Q4 2025 and bottomed at $52.5 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $304.6 million, with a median of $225.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 49.17% in 2022, then soared 829.6% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $109.9 million in 2021, then crashed by 35.28% to $71.1 million in 2022, then skyrocketed by 380.52% to $341.9 million in 2023, then skyrocketed by 77.99% to $608.5 million in 2024, then grew by 27.82% to $777.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SYRE at $777.8 million in Q4 2025, $504.6 million in Q3 2025, and $538.8 million in Q2 2025.